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adults. Pancreatic abnormalities were discriminatory in both, 
whereas other extra-renal characteristics had a large effect 
size only in adults.  Conclusion: The HNF1B score was dis-
criminatory for  HNF1B mutations in a large cohort of indi-
viduals tested in a single UK centre. The lower NPV (85 vs. 
99%) reduces its clinical utility in selecting patients for  HNF1B 
genetic testing, although validation in a prospective cohort 
is required.  © 2015 S. Karger AG, Basel 
 Introduction 
 Heterozygous mutations in the gene encoding the 
transcription factor hepatocyte nuclear factor 1β (HNF1B) 
result in a multi-system disorder. They are the most com-
monly known monogenic cause of developmental kidney 
disease, which is present in the majority of cases  [1–3] . 
The renal phenotype is very variable; cysts are the most 
frequent feature but single kidneys, hypoplasia, horse-
shoe kidneys, duplex kidneys, collecting system abnor-
malities, bilateral hydronephrosis and hyperuricaemic 
nephropathy may also be seen  [1, 4–10] . HNF1B-related 
disease is often detected on prenatal ultrasound scanning, 
where bilateral hyperechogenic kidneys with normal or 
slightly increased size are commonly found  [11] . Other 
clinical features include young-onset diabetes, pancreatic 
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 Abstract 
 Background/Aims: Diagnosing hepatocyte nuclear factor 
1β (HNF1B)-related disease is a challenging task due to the 
phenotypic variability and frequent absence of a family his-
tory. An HNF1B score has recently been developed to help 
select appropriate patients for genetic testing with a nega-
tive predictive value (NPV) of 99%. We aimed at testing the 
clinical utility of this score in a large number of referrals for 
 HNF1B genetic testing to the UK diagnostic testing service 
for the  HNF1B gene.  Methods: An HNF1B score was assigned 
for 686 UK referrals for  HNF1B genetic testing using clinical 
information available at referral. The performance of the 
score was evaluated by receiver-operating characteristic 
curve analysis. The relative discriminatory ability of different 
clinical features for making a genetic diagnosis of HNF1B-
related disease were estimated in the UK dataset alone and 
pooled with French data.  Results: The HNF1B score discrim-
inated between patients with and without a mutation rea-
sonably well with an area under the curve of 0.72. Applying 
the suggested cut-off score of  ≥ 8 gave a NPV of 85%. In a 
pooled analysis, antenatal renal abnormalities, renal hyper-
echogenicity and cysts were discriminatory in children, 
whereas renal hypoplasia and cysts were discriminatory in 
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hypoplasia, genital tract malformations, deranged liver 
function tests, hypomagnesaemia, hyperuricaemia and 
early-onset gout  [9, 10, 12–17] . Genetic changes comprise 
whole-gene deletions in approximately 50% of patients 
and base substitutions or small insertions-deletions in the 
remainder  [7, 18] . Both may arise spontaneously;  de novo 
whole-gene deletions are seen in about 50% of cases  [6, 
11, 19] . This means there is often no family history of re-
nal disease or diabetes.
 Given the marked clinical heterogeneity of HNF1B-
related disease and frequent absence of a relevant family 
history, diagnosis is often challenging and it is likely that 
many cases remain undetected. Faguer and colleagues 
have recently developed a HNF1B score as a tool to help 
healthcare professionals select appropriate patients for 
genetic testing ( table  1 )  [20] . It is calculated using 17 
items, which include family history, antenatal discovery 
and organ involvement. The score performed well when 
tested in a cohort of 433 patients referred to the  University 
 Hospital of Toulouse in France for  HNF1B gene analysis, 
with a negative predictive value (NPV) >99% and sensi-
tivity of 98.2% using a cut-off score of 8. We aimed at 
replicating this study by testing the clinical utility of the 
HNF1B score in a cohort of 686 patients who had under-
gone genetic testing for  HNF1B mutations at Exeter Mo-
lecular Genetics Laboratory, which provides the UK 
 national diagnostic testing service for the  HNF1B gene.
 Concise Methods 
 Probands with renal disease referred for  HNF1B genetic testing 
to Exeter Molecular Genetics Laboratory from 1998 to 2012 were 
included; the criterion for referral was suspicion of HNF1B-related 
disease by the referring clinician. Informed consent was obtained 
from individuals to perform genetic testing as part of their clinical 
care and the study was conducted in agreement with the Declara-
tion of Helsinki Principles. Mutation screening was performed by 
sequencing of coding exons and exon-intron boundaries together 
with gene dosage assessment by multiplex ligation-dependent 
Table 1.  HNF1B score created by Faguer and colleagues [20]
Characteristics Item Value
Family history +2
Antenatal renal abnormalities Uni/bilateral abnormality by prenatal renal ultrasound scanning +2
Kidneys and urinary tract
Left kidney Hyperechogenicity +4
Renal cysts +4
Hypoplasia +2
Multicystic and dysplastic kidney +2
Urinary tract malformation +1
Solitary kidney +1
Right kidney Hyperechogenicity +4
Renal cysts +4
Hypoplasia +2
Multicystic and dysplastic kidney +2
Urinary tract malformation +1
Solitary kidney +1
Electrolyte or uric acid disorders Low serum Mg2+ (<0.7 mmol/l) +2
Low serum K+ (<3.5 mmol/l) +1
Early-onset gout (>30 years of age) +2
Pathological findings Oligomeganephronia or glomerular cysts +1
Pancreasa MODY or hypoplasia of tail and neck of the pancreas 
or pancreatic exocrine insufficiency
+4
Genital tract Genital tract abnormalityb +4
Liver Liver test abnormalities of unknown originc +2
 HNF1B = Hepatocyte nuclear factor 1β; MODY = maturity-onset diabetes of the young.
This score should be assessed after ruling out easily recognisable inherited renal diseases, e.g., autosomal dominant or recessive poly-
cystic kidney disease and renal coloboma syndrome.
a Maximal value of the item pancreas is 4.
b Bicornuate uterus, hemiuterus, uterus and upper vagina aplasia, epididymal cysts, bilateral absence of vas deferens.
c After exclusion of autoimmune, toxic or viral hepatitis.
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probe amplification as previously described  [7, 19] . Clinical details 
were obtained from referral information and used to assign an 
HNF1B score as described by Faguer et al.  [20] .
 The characteristics of interest were renal structural anomalies 
not due to other recognised causes (including antenatal renal ab-
normalities, hyperechogenicity, cysts, hypoplasia, multicystic dys-
plastic kidney, urinary tract malformations, solitary kidney and 
glomerular cysts/oligomeganephronia on biopsy), young-onset 
diabetes (defined by age at diagnosis  ≤ 35 years), pancreatic hypo-
plasia or evidence of pancreatic exocrine failure (either reduced 
faecal elastase or requirement for enzyme replacement therapy), 
a positive family history of either renal disease or diabetes in par-
ent/child, genital tract malformations (including aplasia of the 
uterus and upper vagina, bicornuate uterus, hemiuterus, absence 
of vas deferens and epididymal cysts), liver test abnormalities of 
unknown aetiology, hypomagnesaemia (serum Mg 2+ <0.7 mmol/l) 
and early-onset gout (defined by age at diagnosis <30 years).
 The discriminatory ability of clinical features was determined 
by comparing proportions in patients with and without an  HNF1B 
gene mutation. Pooled odds ratios (OR) were estimated for differ-
ent characteristics using both this UK dataset and published data 
in the recent paper by Faguer et al. from a cohort of 433 patients 
referred to the University Hospital of Toulouse in France for 
 HNF1B gene analysis  [20] .
 Performance of the HNF1B score in the UK cohort was evalu-
ated by receiver-operating characteristic (ROC) curve analysis. 
NPV, positive predictive value (PPV), sensitivity and specificity 
were calculated using the recommended cut-off score of 8.
 Statistical Analyses 
 Differences in the frequencies of clinical features and HNF1B 
score were assessed using the Fisher’s exact test for categorical vari-
ables and the Mann-Whitney U test for continuous variables. Ef-
fect size estimates were summarised using OR with 95% confi-
dence intervals (CI). Pooled OR were estimated using the Mantel-
Haenszel method with a calculation of 95% CI using the Robins, 
Breslow and Greenland variance formula. Discrimination between 
patients with and without an  HNF1B mutation was assessed by 
determining the area under the curve of the ROC curve derived 
from the score. A p value of <0.05 was considered to be  statistically 
significant. All analyses were carried out using SPSS (version 22) 
and StatsDirect (version 2.7.8) statistical software.
 Results 
 UK Cohort Description 
 The cohort included 686 unrelated patients, with a 
male:female ratio of 1: 1. Four hundred and sixteen indi-
viduals (60.6%) were aged  ≤ 16. The majority of the cohort 
had a congenital anomaly of the kidney or urinary tract 
(CAKUT): 408 children (98.1%) and 246 adults (91.1%). 
A total of 177 patients (25.8%) from the 686 referred for 
genetic testing were found to have a heterozygous  HNF1B 
gene anomaly: 78 (44.1%) had base substitutions or small 
insertions-deletions, 92 (52.0%) had whole-gene dele-
tions and 7 had partial-gene deletions (4.0%).
 The characteristics of the cohort are summarised in 
 table 2 . In the paediatric population, detection of antenatal 
renal abnormalities, renal hyperechogenicity and renal 
cysts were all more common in  HNF1B mutation carriers 
(p = 0.0003, p = 0.0008 and p = 0.001, respectively). This is 
in contrast to the adult population where hypoplasia was 
the only discriminatory renal characteristic (p < 0.0001). 
Young-onset diabetes was the only clinical feature to dis-
criminate between patients with and without an  HNF1B 
mutation in both the paediatric and adult cohorts (p = 
0.0002 and p < 0.0001, respectively). The median age at 
diagnosis of diabetes was also lower in those with HNF1B-
related disease at 16.5 years (IQR  12–26.8) compared to 
those without (median age 32.5, IQR 15.3–49.8), 
p < 0.0001. Pancreatic hypoplasia and/or exocrine failure 
was significantly associated with  HNF1B mutations in 
adults (p = 0.0006) but not children; however, there was 
only one affected patient in the paediatric cohort and so 
the numbers were too small to draw any conclusions. In 
the paediatric population, the frequency of other clinical 
features and a positive family history of renal disease or 
diabetes did not vary between patients with and without a 
diagnosis of HNF1B-related disease. However, in the adult 
population genital tract malformations, liver test abnor-
malities and hypomagnesaemia were all discriminatory 
(p = 0.01, p < 0.0001 and p < 0.0001, respectively).
 Estimation of Effect Size in UK and French Cohorts 
 We then used pooled data from UK and French co-
horts to see if the same clinical features were discrimina-
tory; pooled OR were used to estimate effect size for the 
different characteristics ( fig. 1 ). In the paediatric referrals, 
antenatal renal abnormalities, renal hyperechogenicity 
and cysts were the renal characteristics with the largest 
OR of 2.5 (95% CI 1.7–3.7), 4.4 (95% CI 2.7–7.2) and 2.5 
(95% CI 1.6–3.8), respectively. OR for young-onset dia-
betes and pancreatic hypoplasia/exocrine failure were 2.9 
(95% CI 1.6–5.1) and 15.9 (95% CI 1.8–143). In the adult 
referrals, hypoplasia and cysts were the renal structural 
anomalies with the highest OR (3.6, 95% CI 1.9–7.1, and 
1.9, 95% CI 1.1–3.2, respectively). OR for the pancreatic 
phenotype were similar to those seen in children. Large 
OR were seen for genital tract malformations (2.5, 95% 
CI 1.1–5.2), liver test abnormalities (10.1, 95% CI 4.5–23) 
and hypomagnesaemia (15.5, 95% CI 4.6–52). This is in 
contrast to the paediatric population where the OR for 
these other clinical features were all <1. The 95% CI for 
some of these characteristics, such as pancreatic hypopla-
sia or exocrine failure, are very wide and this reflects the 
small number of patients affected.
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 Evaluation of HNF1B Score in UK Cohort 
 The median HNF1B score was higher in patients with 
an  HNF1B mutation as compared with those without (10 
(IQR 8–13.5) vs. 8 (IQR 4–10), p < 0.0001). There was no 
significant difference in score between those with whole-
gene deletions and those with base substitutions or small 
insertions-deletions. The ROC curve, with  HNF1B  genetic 
test result as the dependent variable, is shown in  figure 2 ; 
area under the curve = 0.72 (95% CI 0.67–0.76). Using the 
suggested cut-off score of 8 gave a sensitivity of 80%, 
 specificity of 38%, NPV of 8% and PPV of 31%. The sta-
tistical performance of the HNF1B score using different 
Table 2.  Characteristics of 686 patients tested for a HNF1B mutation at Exeter Molecular Genetics Laboratory
Total
HNF1B status
p
OR (95% CI)
Children (≤16 years)
HNF1B status
p
OR (95% CI)
Adults (>16 years)
 HNF1B status
p
OR (95% CI)
mutation, %
(n = 177)
normal, %
(n = 509)
mutation, %
(n = 116)
normal, %
(n = 300)
mut ation, %
(n = 61)
normal, %
(n = 209)
Renal phenotype
Antenatal renal 
abnormalities
54 (30.5) 83 (16.3) <0.0001
2.3 (1.5–3.4)
53 (45.7) 80 (26.7) 0.0003
2.3 (1.5–3.6)
1 (1.6) 3 (1.4) 1
1.1 (0.1–11.2)
Hyperechogenicity 23 (13.0) 22 (4.3) 0.0002
3.3 (1.8–6.1)
21 (18.1) 20 (6.7) 0.0008
3.1 (1.6–6.0)
2 (3.3) 2 (1.0) 0.2
3.5 (0.5–25.4)
Renal cysts 136 (76.8) 314 (61.7) 0.0002
2.1 (1.4–3.0)
93 (80.2) 190 (63.3) 0.001
2.3 (1.4–3.9)
43 (70.5) 124 (59.3) 0.1
1.6 (0.9–3.0)
Hypoplasia 21 (11.9) 24 (4.7) 0.002
2.7 (1.5–5.0)
6 (5.2) 16 (5.3) 1
1.0 (0.4–2.5)
15 (24.6) 8 (3.8) <0.0001
8.2 (3.3–20.5)
Multicystic and 
dysplastic kidney
6 (3.4) 26 (5.1) 0.4
0.7 (0.3–1.6)
6 (5.2) 25 (8.3) 0.3
0.6 (0.2–1.5)
0 1 (0.5) 1
0 (0–65.1)
Urinary tract 
malformations
19 (10.7) 52 (10.2) 0.9
1.1 (0.6–1.8)
13 (11.2) 29 (9.7) 0.7
1.2 (0.6–2.4)
6 (9.8) 23 (11.0) 1
0.9 (0.3–2.3)
Solitary kidney 14 (7.9) 54 (10.6) 0.4
0.7 (0.4–1.3)
6 (5.2) 21 (7) 0.7
0.7 (0.3–1.8)
8 (13.1) 33 (15.8) 1
0.8 (0.4–1.8)
Glomerular cysts or 
oligomeganephronia 
on biopsy
4 (2.3) 10 (2.0) 0.8
1.2 (0.4–3.7)
2 (1.7) 8 (2.7) 0.7
0.6 (0.1–3.1)
2 (3.3) 2 (1.0) 0.2
3.5 (0.5–25.4)
Pancreas phenotype
Diabetes with age of 
onset ≤35 years
60 (33.9) 59 (11.6) <0.0001
3.9 (2.6–5.9)
26 (22.4) 25 (8.3) 0.0002
3.2 (1.7–5.8)
34 (55.7) 34 (16.3) <0.0001
6.5 (3.5–12.1)
Hypoplasia or 
exocrine failure
7 (4.0) 1 (0.2) 0.0004
20.7 (2.5–169)
1 (0.9) 0 0.3
–
6 (9.8) 1 (0.5) 0.0006
22.7 (2.7–192)
Other features
Family history 64 (36.2) 184 (36.1) 1
1.0 (0.7–1.4)
36 (31.0) 76 (25.3) 0.3
1.3 (0.8–2.1)
28 (45.9) 108 (51.7) 0.5
0.8 (0.4–1.4)
Genital tract 
malformations
9 (5.1) 16 (3.1) 0.2
1.7 (0.7–3.8)
1 (0.9) 8 (2.7) 0.5
0.3 (0.04–2.6)
8 (13.1) 8 (3.8) 0.01
3.8 (1.4–10.6)
Liver test 
abnormalities
15 (8.5) 5 (1.0) <0.0001
9.3 (3.3–26.1)
0 2 (0.7) 1
0 (0–9.0)
15 (24.6) 3 (1.4) <0.0001
22.4 (6.2–80.5)
Hypomagnesaemia 11 (6.2) 7 (1.4) 0.001
4.8 (1.8–12.5)
3 (2.6) 6 (2) 0.7
1.3 (0.3–5.3)
8 (13.1) 1 (0.5) <0.0001
31.4 (3.8–257)
Early-onset gout 3 (1.7) 13 (2.6) 0.8
0.7 (0.2–2.3)
1 (0.9) 6 (2) 0.7
0.4 (0.05–3.6)
2 (3.3) 7 (3.3) 1
1.0 (0.2–4.8)
CI = Confidence interval; HNF1B = hepatocyte nuclear factor 1β; OR = odds ratio.
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 Fig. 2. ROC curve showing the discrimina-
tive ability of the  HNF1B score for all refer-
rals for  HNF1B genetic testing to Exeter 
Molecular Genetics Laboratory. c-statis-
tic  = 0.72 (95% CI 0.67–0.76). c-statistic 
was 0.71 (95% CI 0.65–0.76) in the paedi-
atric cohort and 0.75 (95% CI 0.69–0.82) in 
the adult cohort. CI = Confidence interval. 
 Fig. 1. Forest plot showing the pooled OR for making a genetic di-
agnosis of HNF1B-related disease for different clinical features in 
the paediatric ( a ) and the adult cohorts ( b ) of the combined refer-
rals for  HNF1B genetic testing to both Exeter, UK and Toulouse, 
France (n = 1,119). Other renal  abnormalities include multicystic 
dysplastic kidney, urinary tract malformations, single kidney and 
glomerular cysts/oligomeganephronia on biopsy. CI = Confidence 
interval; DM = diabetes mellitus; HNF1B = hepatocyte nuclear fac-
tor 1β; OR = odds ratio. 
Early-onset gout
Hypomagnesaemia
Liver test abnormalities
Genital tract malformations
Family history
Pancreatic hypoplasia/exocrine failure
Young-onset DM
Other renal abnormalities
Renal hypoplasia
Renal cysts
Renal hyperechogenicity
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Other
Pancreatic
Renal
Early-onset gout
Hypomagnesaemia
Liver test abnormalities
Genital tract malformations
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cut-off scores is shown in online supplementary table S1 
(for all online suppl. material, see www.karger.com/doi/ 
10.1159/000398819).
 Discussion 
 In this study, we retrospectively generated an HNF1B 
score for 686 referrals for  HNF1B genetic testing to one 
UK centre and found it discriminated between patients 
with and without a mutation reasonably well with an area 
under the curve of 0.72. This provides further evidence 
that this clinical scoring system may be a useful screening 
tool to select individuals for  HNF1B genetic testing. Ap-
plying the suggested cut-off score of 8 gave a sensitivity of 
80% and an NPV of 85%, so this threshold cannot be reli-
ably used to exclude individuals with a lower score from 
genetic testing.
 This work had limitations, which may explain the low-
er NPV of the HNF1B score in this cohort (85 vs. 99.4% 
in the original French cohort). Thirty five confirmed 
 HNF1B mutation carriers in our referrals had a score be-
low 8, and so they would not have been initially consid-
ered for  HNF1B genetic testing according to the diagnos-
tic strategy suggested by Faguer and colleagues  [20] . Some 
of these false negative results may be the result of the score 
being calculated retrospectively using clinical details 
available at the time of referral. These were based on rou-
tinely collected clinical information so not all character-
istics were systematically assessed for. We also included 
all patients who underwent  HNF1B genetic testing at our 
centre from 1998 to 2012 and some of the clinical features, 
such as hypomagnesaemia, have only been associated 
with HNF1B-related disease in recent years. Use of the 
HNF1B score is suggested as part of a diagnostic algo-
rithm where genetic testing should be reconsidered in in-
dividuals with a score <8 if new features suggestive of 
HNF1B-related disease occur. Many of the patients in our 
dataset may have scored  ≥ 8 with more complete data dur-
ing follow-up. It will therefore be important to assess the 
performance of the score in a prospective study.
 There are differences between the UK and French da-
tasets. In the UK cohort, many of the renal structural 
anomalies were less common in individuals regardless of 
their  HNF1B status compared to a large group of patients 
referred to a centre in France for  HNF1B gene analysis; 
antenatal renal abnormalities were seen in 137/686 
(20.0%) UK referrals but 153/433 (35.3%) French refer-
rals  [20] . In contrast, young-onset diabetes was more 
prevalent in the UK cohort with 33.9% of  HNF1B muta-
tion carriers affected compared to only 5.4% in the French 
dataset. These differences are likely to reflect the fact that 
the Exeter Molecular Genetics Laboratory has a particular 
interest in maturity-onset diabetes of the young (MODY), 
whereas the University Hospital of Toulouse specialises 
in inherited renal disease. However, it also highlights the 
importance of appropriate counselling and monitoring 
for diabetes in affected individuals and their families. In 
both UK and French datasets, patients underwent genet-
ic testing based on clinician suspicion of HNF1B-related 
renal disease and the majority had CAKUT. This has led 
to a selection bias that limits the applicability of the study 
results. This is in keeping with the literature to date, where 
the majority of cohorts with HNF1B-related disease that 
have been described were pre-selected for particular kid-
ney abnormalities  [1–4, 6, 7, 9, 11, 19] .
 In the absence of any current population-based data, 
these two large datasets provide an important source of 
information on HNF1B-related disease. Similar clinical 
features discriminated between patients with and without 
an  HNF1B mutation in both UK and pooled datasets, 
with both showing differences between paediatric and 
adult cohorts. Antenatal renal abnormalities, renal hy-
perechogenicity and cysts were discriminatory in chil-
dren, whereas renal hypoplasia and cysts were discrimi-
natory in adults. Pancreatic abnormalities were discrimi-
natory in both age groups whereas genital tract 
malformations, liver test abnormalities and hypomagne-
saemia all had a large effect size in adults only. Due to the 
small numbers, some of the OR have very large CI so the 
true effect size is difficult to estimate. However, the data 
suggests that the antenatal detection of renal hyperecho-
genicity or cysts plus the presence of either diabetes or 
pancreatic hypoplasia in children should prompt clini-
cians to consider a diagnosis of HNF1B-related disease. 
In adults, the renal phenotype seems to be less discrimi-
natory, so extra-renal features are worth testing for in or-
der to decide whether genetic testing may be required. 
The collection of systematic data on clinical features and 
biomarkers in a large cohort of  HNF1B mutation carriers 
unselected for phenotype will allow more accurate mod-
elling in different age groups and may lead to the evolu-
tion of a simpler score based only on the most discrimina-
tive features.
 In summary, we have replicated the discriminative 
power of the recently described HNF1B score in a large 
cohort of individuals referred for  HNF1B genetic testing 
to one UK centre. The lower NPV and sensitivity using 
the suggested cut-off of 8 would have led to missed cases 
of HNF1B-related disease in this dataset. This highlights 
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the need for validation in a prospective cohort and recal-
culation of the score if a new feature of HNF1B-related 
disease occurs.
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